An International, Seamless Phase II/III Responsive Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GBM AGILE)
Sponsor: |
Global Coalition for Adaptive Research |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS2589 |
U.S. Govt. ID: |
NCT03970447 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called study drugs and are not approved by the Food and Drug Administration (FDA) to be used for your type of cancer. The investigational treatments in this study have been previously tested in people.
Investigator
Andrew Lassman, MD
Are you at least 18 years old? |
Yes |
No |
Do you have a newly diagnosed or recurrent glioblastoma? |
Yes |
No |
Are you willing and able to provide written informed consent and to comply with the study protocol? |
Yes |
No |